World Library  
Flag as Inappropriate
Email this Article

Entacapone

Article Id: WHEBN0003208946
Reproduction Date:

Title: Entacapone  
Author: World Heritage Encyclopedia
Language: English
Subject: Tolcapone, COMT inhibitor, Lazabemide, Talipexole, Safinamide
Collection: Amides, Catechols, Comt Inhibitors, Nitriles, Nitrobenzenes
Publisher: World Heritage Encyclopedia
Publication
Date:
 

Entacapone

Entacapone
Systematic (IUPAC) name
(2E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide
Clinical data
Trade names Comtan (single ingredient), Stalevo (multi-ingredient)
AHFS/Drugs.com
MedlinePlus
Licence data US Daily Med:
Pregnancy
category
  • AU: B3
  • US: C (Risk not ruled out)
Legal status
Routes of
administration
Oral
Pharmacokinetic data
Bioavailability 35%
Protein binding 98% (binds to serum albumin)
Metabolism Hepatic
Biological half-life 0.4-0.7 hour
Excretion Faeces (90%), Urine (10%)
Identifiers
CAS Registry Number  Y
ATC code N04
PubChem CID:
IUPHAR/BPS
DrugBank  Y
ChemSpider  Y
UNII  Y
KEGG  Y
ChEBI  Y
ChEMBL  Y
Synonyms
Chemical data
Formula C14H15N3O5
Molecular mass 305.286 g/mol
 Y   

Entacapone (INN) ( or ) is a drug that functions as a catechol-O-methyl transferase (COMT) inhibitor. It is used in the treatment of Parkinson's disease.

When administered in conjunction with dopaminergic agents such as L-DOPA, entacapone prevents COMT from metabolizing L-DOPA into 3-methoxy-4-hydroxy-L-phenylalanine (3-OMD) in the periphery, which does not easily cross the blood–brain barrier (BBB). Pharmacologically, entacapone is somewhat similar to carbidopa or benserazide, in that it is an inhibitor of an enzyme that converts L-DOPA into a compound that cannot cross the blood–brain barrier. Carbidopa and benserazide inhibit aromatic L-amino acid decarboxylase, which converts L-DOPA into dopamine, which cannot cross the blood–brain barrier.

Entacapone is a member of the class of drugs known as nitrocatechols.

Contents

  • Side effects 1
  • Products 2
  • References 3
  • External links 4

Side effects

The most frequent undesirable effects caused by entacapone relate to the increased effects of L-DOPA, such as involuntary movements (dyskinesias). These occur most frequently at the beginning of entacapone treatment. Others common side effects are gastrointestinal problems, including nausea and abdominal pains. Diarrhea is a frequently reported and troublesome side effect that can result in unnecessary investigation, but resolves quickly on withdrawal of the drug.[1] Entacapone may cause urine to turn reddish-brown. This is a harmless side effect and is not a cause for concern. In studies with entacapone, some people have reported experiencing a dry mouth.

Products

Entacapone is developed by Orion Pharma and marketed by Novartis under the trade name COMTan in the United States.

Stalevo is another medication developed by Orion Pharma and marketed by Novartis that contains entacapone in combination with carbidopa and levodopa (active ingredients in Sinemet).

References

  1. ^ Singer C (2002). "Adverse effects in the treatment of Parkinson’s disease". Expert Review of Neurotherapeutics 2 (1): 105–118.  

External links

  • Entacapone/Carbidopa/Levodopa (marketed as Stalevo) Information (FDA)
  • Entacapone (Medline plus/NIH)
  • Comtan (manufacturer's website)
  • Stalevo (manufacturer's website)
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 



Copyright © World Library Foundation. All rights reserved. eBooks from World eBook Library are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.